MyFinsight
Home
Blog
About
Sales and maturities
of marketable...
$68,125K
(-78.99%↓ Y/Y)
Net cash provided by
investing activities
$34,315K
(-65.99%↓ Y/Y)
Canceled cashflow
$33,810K
Net (decrease)
increase in cash and cash...
-$2,769K
(-112.03%↓ Y/Y)
Canceled cashflow
$34,315K
Stock-based compensation
expense
$3,381K
(-70.90%↓ Y/Y)
Accounts payable
$612K
(-86.05%↓ Y/Y)
Depreciation and
amortization expense
$104K
(-50.00%↓ Y/Y)
Purchases of marketable
securities
$33,810K
(-84.86%↓ Y/Y)
Net cash used in
operating activities
-$37,084K
(41.54%↑ Y/Y)
Canceled cashflow
$4,097K
Other segment items
-$2,166K
Net loss
-$32,933K
(53.90%↑ Y/Y)
Accrued expenses and
other liabilities
-$5,645K
(-116.95%↓ Y/Y)
Canceled cashflow
$2,166K
Prepaid expenses and
other current assets
$2,009K
(215.26%↑ Y/Y)
Accretion of premium and
discounts on marketable...
$542K
(-82.29%↓ Y/Y)
Operating lease
liabilities
-$52K
(45.26%↑ Y/Y)
Total research and
development expense
$26,389K
Total general and
administrative
$5,329K
Stock based
compensation
$3,381K
Back
Back
Cash Flow
Atea Pharmaceuticals, Inc. (AVIR)
Atea Pharmaceuticals, Inc. (AVIR)
source: myfinsight.com